By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Quest PharmaTech Inc. 

9411 20 Avenue

Edmonton  Alberta  T6N 1E5  Canada
Phone: 780-448-1400 Fax: 780-416-0324



Company News
Quest PharmaTech Inc. Expands Its Consumer Health Product Pipeline With Clinically Validated Natural Allergy Relief 5/4/2017 12:11:26 PM
Quest PharmaTech Inc. Retains Haft Group For Financial Services 9/6/2016 1:56:14 PM
Quest PharmaTech Inc.'s Subsidiary, OncoQuest, Signs Agreement With Shenzhen Hepalink Pharmaceutical Co., Ltd. To Fund Immunotherapy For Treatment Of Cancer In China 3/22/2016 7:44:26 AM
Quest PharmaTech Inc. Receives U.S. $2 Million For Its Immuno-Photodynamic Therapy Assets 12/10/2015 8:14:16 AM
Quest PharmaTech Inc.'s Subsidiary, OncoQuest, Closes U.S. $13,000,000 Preferred Share Private Placement With Hepalink USA To Fund Immunotherapy For Treatment Of Cancer 11/18/2015 8:47:21 AM
Quest PharmaTech Inc. Closes $1,000,000 Private Placement 7/28/2015 12:22:28 PM
Quest PharmaTech Inc. Announces Funding Support From National Research Council's Industrial Research Assistance Program For Ige Antibody Cancer Immunotherapy Development (Allergooncology) 1/13/2015 10:19:16 AM
Quest PharmaTech Inc. Completes Patient Enrollment In Phase 2b Study Of Oregovomab For The Immunotherapy Of Ovarian Cancer 6/10/2014 8:58:58 AM
Q&A Interview With CEO Of Quest PharmaTech Inc. (TSX.V: QPT) 1/22/2014 9:48:13 AM
Quest PharmaTech Inc. Strengthens its Antibody Immunotherapy Technology by Licensing Anti-Muc1 IGE Technology From Stanford University; Researchers to Present Late-Breaking Data at the 28th Annual Meeting of the Society For Immunotherapy of Cancer to be Held November 8 - 10, 2013 In Maryland, U.S. 11/7/2013 10:47:54 AM